Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ageLOC Meta (marketed as ageLOC Reset in some international regions) is a multi-ingredient dietary supplement developed by Nu Skin Enterprises under the Pharmanex brand. The formulation features a proprietary blend of anthocyanins—specifically cyanidin and delphinidin derived from black currant, bilberry, and black rice—paired with a prebiotic blend of inulin and fructooligosaccharides. The supplement is designed to support 'metabolic flexibility' by modulating the gut microbiome, enhancing intestinal barrier integrity through the support of tight junction proteins, and reducing oxidative stress and systemic inflammation by targeting reactive oxygen species and nuclear factor kappa B pathways. While not an FDA-approved pharmaceutical for specific diseases, it has been clinically studied for its ability to improve core metabolic health markers and promote a healthy microbial environment, particularly in populations dealing with metabolic stress, overweight, or obesity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ageLOC Meta.